Charles H. Weaver, MD

Charles H. Weaver, MD, is a former cancer researcher and pioneer of Internet-based cancer education. Dr. Weaver received his medical training at the University of Washington, University of Pennsylvania, National Institutes of Health, and Fred Hutchinson Cancer Research Center. Dr. Weaver’s initial clinical research interests included stem cell technology, breast cancer, and lymphomas. He has authored 75 articles in major medical journals including the Journal of Clinical Oncology, Blood, Cancer, Bone Marrow Transplantation and the New England Journal of Medicine.

Dr. Weaver served five years as the Chief Medical Officer of a Physician Practice Management (PPM) company, where he created the clinical trials network and was responsible for both patient and physician education. During this time he also developed cancer treatment strategies and educational programs used by over 750 oncologists and was invited to lecture extensively in the U.S. and Europe at institutions that included the University of London and University of Heidelberg.

In 1998, Dr. Weaver founded a multi-media healthcare publishing company that would become OMNI Health Media (OHM),, an award-winning, leading Internet cancer portal used by over 200,000 cancer patients and oncology professionals each month. OHM has developed and implemented online market research programs and CME for professionals and has developed an Internet-based consumer cancer education platform that has been used by over 250 cancer centers and clinics. In 2006, Dr. Weaver founded Women magazine (formerly Women&Cancer) a quarterly print and online magazine dedicated to covering women’s health and wellness issues, where he continues to serve as Executive Editor and Publisher.

Dr. Weaver is significantly involved with cancer advocacy, education and women’s health issues, and has appeared on the Today show to discuss these issues. He has written extensively on all aspects of cancer management. Most recently he founded, the leading social network for cancer patients. is currently used by over 15,000 cancer patients and is licensed by Roswell Park, MSKCC, Harvard-DFCI, Vanderbilt, Ohio State, Fred Hutchinson, and other leading cancer centers.

Click here to contact.